{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:57Z","timestamp":1787017077155,"version":"build-2736575974"},"reference-count":15,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,6,1]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>\n                    This clinical case series describes our experience with the use of Janus kinase 1\/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still\u2019s disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of\n                    <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                    infection following baricitinib use.\n                  <\/jats:p>","DOI":"10.1136\/rmdopen-2020-001246","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T11:32:00Z","timestamp":1594812720000},"page":"e001246","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease"],"prefix":"10.1136","volume":"6","author":[{"given":"Mark","family":"Kacar","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fitton","sequence":"additional","affiliation":[{"name":"Institue of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K","family":"Gough","sequence":"additional","affiliation":[{"name":"Rheumatology, Harrogate District Hospital, Harrogate, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis G","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Institue of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-0554","authenticated-orcid":false,"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[{"name":"Institue of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Department of Clinical Immunology and Allergy, St James\u2019s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"2025090312511784000_6.2.e001246.1","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2025090312511784000_6.2.e001246.2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200205000-00003"},{"key":"2025090312511784000_6.2.e001246.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.86336","article-title":"Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology","volume":"1","author":"Harrison","year":"2016","journal-title":"JCI Insight"},{"key":"2025090312511784000_6.2.e001246.4","doi-asserted-by":"crossref","unstructured":"Alten R , Gomez-Reino J , Durez P , et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskelet Disord 2011;12. doi: 10.1186\/1471-2474-12-153","DOI":"10.1186\/1471-2474-12-153"},{"key":"2025090312511784000_6.2.e001246.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.10870"},{"key":"2025090312511784000_6.2.e001246.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"2025090312511784000_6.2.e001246.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204405"},{"key":"2025090312511784000_6.2.e001246.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025090312511784000_6.2.e001246.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025090312511784000_6.2.e001246.10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.semarthrit.2015.10.003","article-title":"Adult onset Still\u2019s disease associated with malignancy-cause or coincidence?","volume":"45","author":"Hofheinz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312511784000_6.2.e001246.11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000446062","article-title":"Autoimmunity and inflammation in myelodysplastic syndromes","volume":"136","author":"Wolach","year":"2016","journal-title":"Acta Haematol"},{"key":"2025090312511784000_6.2.e001246.12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2018.07.009","article-title":"Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review","volume":"18","author":"Seguier","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025090312511784000_6.2.e001246.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"2025090312511784000_6.2.e001246.14","doi-asserted-by":"crossref","unstructured":"Hu Q , Wang M , Jia J , et al. Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China. Ann Rheum Dis 2020;pii:annrheumdis-2019-216699. doi: 10.1136\/annrheumdis-2019-216699","DOI":"10.1136\/annrheumdis-2019-216699"},{"key":"2025090312511784000_6.2.e001246.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98814"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:51:25Z","timestamp":1756929085000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/rmdopen-2020-001246"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001246","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}